Sana Biotechnology (NASDAQ:SANA) Upgraded at TD Cowen

TD Cowen upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports.

Several other brokerages have also issued reports on SANA. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Sana Biotechnology in a research note on Wednesday, November 27th. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.25.

Sana Biotechnology Price Performance

Shares of Sana Biotechnology stock opened at $3.66 on Wednesday. The firm has a 50 day simple moving average of $2.40 and a 200 day simple moving average of $4.06. Sana Biotechnology has a fifty-two week low of $1.52 and a fifty-two week high of $12.00. The firm has a market cap of $817.16 million, a P/E ratio of -2.61 and a beta of 1.45.

Sana Biotechnology (NASDAQ:SANA) last released its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. On average, sell-side analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Insider Activity

In other news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. The trade was a 6.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 31.10% of the stock is currently owned by company insiders.

Institutional Trading of Sana Biotechnology

Several hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Sana Biotechnology in the third quarter worth about $29,000. Stifel Financial Corp bought a new stake in Sana Biotechnology during the 3rd quarter worth approximately $43,000. EP Wealth Advisors LLC acquired a new stake in Sana Biotechnology during the 3rd quarter worth approximately $45,000. Blue Trust Inc. lifted its stake in Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after buying an additional 12,154 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new position in Sana Biotechnology in the third quarter valued at approximately $67,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.